Nephrology and Peritoneal Dialysis
Iperboreal Pharma S.r.l. focuses on end-stage kidney disease and treatments used in peritoneal dialysis, with research centered on dialysis solutions and approaches intended to support renal replacement therapy.
- End-stage kidney disease
- Peritoneal dialysis
- Glucose-sparing dialysis solutions
- Peritoneal ultrafiltration
The sponsor’s clinical portfolio includes investigations of dialysis-related therapies for patients initiating or continuing peritoneal renal support, with attention to kidney function management and treatment tolerability.
Cardiorenal Disease and Heart Failure
The company also investigates therapies relevant to cardiorenal syndrome and congestive heart failure, reflecting an interest in conditions where cardiac and renal dysfunction overlap.
- Congestive heart failure
- Cardiorenal syndrome
- Heart failure exacerbation
- Mortality and clinical worsening
Research activity in this area includes peritoneal ultrafiltration strategies aimed at managing fluid balance and related clinical deterioration in patients with combined cardiac and renal disease.
Pediatric Nephrology
Iperboreal Pharma S.r.l. includes pediatric dialysis within its research landscape, with studies directed toward the safety of dialysis-related treatments in children.
- Pediatric peritoneal dialysis
- Childhood kidney disease
- Treatment safety in children
This area highlights interest in renal therapies adapted to younger patients requiring long-term dialysis care.
Dialysis Solution Innovation
The sponsor’s trials also address the performance of novel peritoneal dialysis solutions, including formulations designed to reduce reliance on glucose and support dialysis efficiency.
- Xylitol-based dialysis solutions
- L-carnitine
- Polydextrin
- Dialysis efficacy and safety
These research interests are centered on improving solute clearance, treatment tolerability, and the clinical practicality of alternative dialysis formulations.
